|
|
1.
|
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. MedStar authors:
Year: 2021
Citation: - Nature Medicine. 27(10):1818-1824, 2021 10.
Department: - MedStar Heart and Vascular Institute
Medline publication type:
All authors: - Axelsson A, Bach RG, Becker JR, Benson L, Braunwald , Bundgaard H, Burns KM, Canter C, Cirino AL, Colan SD, Day SM, Ho CY, Lakdawala NK, Lever HM, MacRae CA, Margossian R, McMurray JJV, Mestroni L, Murphy AM, Orav EJ, Owens AT, Patel AR, Pereira AC, Rossano JW, Russell MW, Seidman CE, Solomon SD, Soslow JH, Taylor MRG, Thrush P, VANISH Investigators, Vargas JD, Wheeler MT, Wilmot I, Zahka K
|
|
|
2.
|
Baseline Characteristics of the VANISH Cohort. MedStar authors:
Year: 2019
Citation: - Circulation: Heart Failure. 12(12):e006231, 2019 12.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Axelsson Raja A, Bach R, Becker J, Benson L, Braunwald E, Bundgaard H, Canter C, Choudhury L, Cirino AL, Colan SD, Day SM, Hall EK, Ho CY, Jefferies JL, Lever H, Lewis GD, Lin KY, MacRae CA, Margossian R, McMurray JJV, Mestroni L, Murphy AM, Orav EJ, Owens AT, Pahl E, Patel AR, Pereira AC, Rossano J, Russell M, Shi L, Solomon SD, Taylor M, Vargas JD, Wheeler MT, Zahka K
|
